Raymond James has expanded its healthcare investment banking practice through the addition of four senior bankers including Doug Brown, who joins the firm as the head of healthcare investment banking, managing directors Mike Drendel and Don Matz, and director Juan Carlos Barreto.
Brown joins the firm with over 25 years of healthcare deal experience and previously served as chief strategy and corporate development officer with NeoGenomics Laboratories. Drendel enters his new position following his time leading specialty and generic pharmaceutical franchises as a senior managing director with SVB Leerink.
Matz joins the firm with 15 years of investment banking history and previously served with SVB Leerink where he concentrated on M&A and capital raising in pharmaceutical services & technology. Barreto also joins the firm with over a decade of investment banking experience and last served at SVB Leerink.
“Raymond James has a strong reputation in the healthcare space paired with a powerful global banking platform that provides clients the expertise and attention required for each unique engagement,” said Brown.